GORMAN KEVIN CHARLES — SEC insider filings
SEC reporting owner CIK 1201096. 37 insider filings on record with FilingPulse; latest filed 2026-09-15.
Transaction summary — filings shown
Covers all 37 filings on record, filed 2020-08-07 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 53 shares, $1,013 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 35 legs across 22 filings — 1,089,999 shares, $140,980,284 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 60.
- Largest priced transaction: sale of 245,088 shares @ $154.33 ($37,824,872) in NEUROCRINE BIOSCIENCES INC, filed 2026-05-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | Director | 28 | — | 32 legs · 1,076,645 sh · $140,803,487 | 50 |
| Xencor Inc (XNCR) | Director | 9 | 1 leg · 53 sh · $1,013 | 3 legs · 13,354 sh · $176,797 | 10 |
Insider filings — GORMAN KEVIN CHARLES
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 14,343 @ $0 · Tax withholding (F): 7,839 @ $156.22 | EDGAR |
| 2026-07-08 | 4 | Xencor Inc (XNCR) | Grant/award (A): 10,302 @ $0 · Grant/award (A): 20,604 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Xencor Inc (XNCR) | Sale (S): 7,527 @ $12.31 | EDGAR |
| 2026-05-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 5,248 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 205,088 @ $43.24 · Sale (S): 245,088 @ $154.33 · Option exercise (M): 205,088 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 5,604 @ $0 · Tax withholding (F): 3,024 @ $124.12 · Option exercise (M): 5,377 @ $0 · Tax withholding (F): 2,901 @ $124.12 · Grant/award (A): 63,724 @ $0 · Tax withholding (F): 34,380 @ $124.12 · +2 more | EDGAR |
| 2026-02-03 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 5,142 @ $0 · Tax withholding (F): 2,845 @ $136.06 · Option exercise (M): 5,142 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 106,322 @ $35.99 · Sale (S): 106,322 @ $126.41 · Option exercise (M): 106,322 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Xencor Inc (XNCR) | Grant/award (A): 13,686 @ $0 · Sale (S): 3,173 @ $9.22 · Grant/award (A): 27,372 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 9,613 @ $120.38 | EDGAR |
| 2025-05-22 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 6,610 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 5,376 @ $0 · Sale (S): 2,832 @ $116.69 · Option exercise (M): 5,603 @ $0 · Sale (S): 3,012 @ $116.68 · Option exercise (M): 5,376 (derivative) @ $0 · Option exercise (M): 5,603 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 4,318 @ $0 · Sale (S): 2,274 @ $118.37 · Option exercise (M): 4,318 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 5,141 @ $0 · Sale (S): 2,707 @ $152.92 · Option exercise (M): 5,141 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 146,105 @ $32.99 · Sale (S): 146,105 @ $149.46 · Option exercise (M): 146,105 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | Xencor Inc (XNCR) | Sale (S): 2,654 @ $20.68 | EDGAR |
| 2024-06-17 | 4 | Xencor Inc (XNCR) | Grant/award (A): 5,986 @ $0 · Grant/award (A): 11,971 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 2,832 @ $133.02 · Grant/award (A): 112,644 (derivative) @ $0 · Grant/award (A): 22,415 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Xencor Inc (XNCR) | Purchase (P): 53 @ $19.12 | EDGAR |
| 2024-02-14 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,778 @ $35.99 · Option exercise (M): 2,312 @ $43.24 · Option exercise (M): 2,778 (derivative) @ $35.99 · Option exercise (M): 2,312 (derivative) @ $43.24 | EDGAR |
| 2024-02-08 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 3,040 @ $142.18 · Sale (S): 2,274 @ $134.15 | EDGAR |
| 2024-02-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 2,707 @ $140.69 | EDGAR |
| 2024-01-10 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 105,835 @ $19.59 · Sale (S): 105,835 @ $132.44 · Option exercise (M): 62,023 @ $19.59 · Sale (S): 62,023 @ $134.01 · Option exercise (M): 105,835 (derivative) @ $19.59 · Option exercise (M): 62,023 (derivative) @ $19.59 | EDGAR |
| 2023-08-23 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 9,328 @ $107.40 | EDGAR |
| 2023-06-22 | 4 | Xencor Inc (XNCR) | Grant/award (A): 5,007 @ $0 · Grant/award (A): 10,013 (derivative) @ $0 | EDGAR |
| 2023-02-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 133,656 (derivative) @ $0 · Grant/award (A): 21,506 (derivative) @ $0 | EDGAR |
| 2023-02-08 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 3,040 @ $105.68 · Sale (S): 3,248 @ $102.30 · Sale (S): 20,482 @ $102.43 · Sale (S): 2,274 @ $104.30 | EDGAR |
| 2023-02-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 2,707 @ $110.08 | EDGAR |
| 2022-06-27 | 4 | Xencor Inc (XNCR) | Grant/award (A): 21,412 (derivative) @ $0 | EDGAR |
| 2022-02-09 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 2,422 @ $80.83 · Sale (S): 3,248 @ $80.82 · Sale (S): 3,040 @ $80.80 · Sale (S): 2,274 @ $79.49 | EDGAR |
| 2022-02-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 140,049 (derivative) @ $0 · Grant/award (A): 20,565 (derivative) @ $0 | EDGAR |
| 2021-06-25 | 4 | Xencor Inc (XNCR) | Grant/award (A): 9,728 (derivative) @ $0 | EDGAR |
| 2021-03-29 | 4/A | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 113,863 (derivative) @ $0 | EDGAR |
| 2021-02-09 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 2,422 @ $114.16 · Sale (S): 2,875 @ $116.79 · Sale (S): 4,343 @ $116.74 · Sale (S): 3,248 @ $116.71 · Grant/award (A): 103,609 (derivative) @ $0 · Grant/award (A): 17,269 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 143,449 @ $8.66 · Sale (S): 143,449 @ $110.21 · Option exercise (M): 164,801 @ $8.65 · Sale (S): 164,801 @ $110.22 · Option exercise (M): 143,449 (derivative) @ $8.66 · Option exercise (M): 164,801 (derivative) @ $8.65 | EDGAR |
| 2020-11-16 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 3,390 @ $90.78 | EDGAR |
| 2020-08-07 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 3,390 @ $118.91 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-06 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1201096 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs